Dr. Reddy’s Laboratories Ltd reported consolidated revenues at Rs. 39.7 billion, year-on-year growth of 3%, for the quarter ended December 31, 2015.
Growth is driven by healthy performance in North America, Europe and India; partially offset by Emerging markets, which were impacted by unfavorable macro-economic conditions.
• Gross Profit Margin at 59.5%, improved by ~130 bps over last year
• Research & Development (R&D) spend at Rs. 4.1 billion. Continued focus on building complex generics and differentiated products pipeline.
9M FY16: Key Highlights
• Consolidated revenues at Rs. 117.1 billion, year-on-year growth of 7%
• Gross Profit Margin at 60.6%, improved by ~200 bps over last year
• Research & Development (R&D) spend at Rs. 13.0 billion. Continued focus on building complex generics and differentiated products pipeline.
Commenting on the company’s third quarter results, Co-chairman and CEO, G V Prasad said, “Despite multiple challenges, we have had a satisfactory quarter in terms of our financial performance. All of our key markets continue to perform well and show healthy growth.
“However, our performance has been impacted due to adverse macro-economic conditions across key emerging market territories. The two approvals and one tentative approval of our NDAs in the very first review cycle has been a positive development and lays the foundation for building a strong and sustainable proprietary products business. Enhancing our quality management practices and meeting the US FDA expectations continues to be our highest priority,” he said. fii-news.com